Abstract: The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula (I) and pyrimidine-thioalkyl and alkylethers of Formula (IA), namely the compounds of Formula (I) where R.sup.4 is selected from the group consisting of --H or --NR.sub.15 R.sub.16 where R.sub.15 is --H and R.sub.16 is --H, C.sub.1 -C.sub.6 alkyl, --NH.sub.2 or R.sub.15 and R.sub.16 taken together with the --N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R.sub.6 is selected from the group consisting of --H, or halo (preferably --Cl); with the overall proviso that R.sub.4 and R.sub.6 are not both --H. The compounds of Formula (IA) are useful in the treatment of individuals who are HIV positive.

Abstract: It has been discovered that rubradirin can be used to treat rubradirin-sensitive, methicillin-resistant staphylococcal infections.

Abstract: This invention relates to the hybridization of streptolydigin, tirandamycin and sorbic acid to penicillin and cephalosporin nuclei.

Abstract: Antibiotic U-66,026 is produced in a fermentation under controlled conditions using the microorganism Alcaligenes sp., NRRL B-15269. Enhanced fermentation of titers U-66,026 are obtained when Alcaligenes sp., NRRL B-15269, is cultivated in mixture with Streptomyces plicatus strain 395, NRRL 15273.Antibiotic U-66,026 is a useful antibiotic which has antifungal activity.

Abstract: Novel antibiotic U-64,864 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces braegensis Dietz sp.n., NRRL 12567. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae. Thus, antibiotic U-64,864 can be used in various environments to eradicate or control such bacteria.

Abstract: Novel antibiotic U-64,864 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces braegensis Dietz sp.n., NRRL 12567. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae. Thus, antibiotic U-64,864 can be used in various environments to eradicate or control such bacteria.

Abstract: Novel antibiotic U-64,767 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces macronensis Dietz sp.n., NRRL 12566. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus and Streptococcus pyogenes. It is also active against the Gram-negative bacterium Streptococcus pneumoniae. Thus, antibiotic U-64,767 can be used in various environments to eradicate or control such bacteria.

Abstract: A novel chemical compound, plasmid pUC1060, which was constructed from Streptomyces sp. 3022a chromosomal DNA and plasmid pBR322. Hybrid plasmid pUC1060 contains a functional tet gene promoter composed of streptomycete and E. coli DNA, and, thus, is useful as a cloning vehicle in recombinant DNA work. For example, using well known DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC1060 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.

Abstract: A novel chemical compound, plasmid pUC1031, which was constructed from Streptomyces sp. 3022a chromosomal DNA and plasmid pBR322. Hybrid plasmid pUC1031 contains a functional tet gene promoter composed of streptomycete and E. coli DNA, and, thus, is useful as a cloning vehicle in recombinant DNA work. For example, using well known DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC1031 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.

Abstract: A process for cloning DNA into a suitable host, which comprises fragmenting said DNA to obtain fragmented DNA, ligating said fragmented DNA into a suitable vector to obtain chimeric (hybrid) DNA, and transforming said chimeric DNA into said ultimate host. By this process, the useful chemical plasmid pUC3, which is obtainable from a biologically pure culture of the microorganism Streptomyces sp. 3022a, NRRL 11441, is cloned into the well-known bacterium E. coli HB101. This cloning of pUC3 into E. coli HB101 enables the production of large amounts of plasmid pUC3 DNA. pUC3 is useful as a cloning vehicle in recombinant DNA work. For example, using recombinant DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC3 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.

Abstract: A novel chemical compound, plasmid pUC1021, which was constructed from Bacillus megaterium chromosomal DNA and plasmid pBR322. Hybrid plasmid pUC1021 contains a functional tet gene promoter, and, thus, is useful as a cloning vehicle in recombinant DNA work. For example, using well known DNA methodology, a desired gene, for example, the insulin gene, can be inserted into pUC1021 and the resulting plasmid can then be transformed into a suitable host microbe which, upon culturing, produces the desired insulin.

Abstract: Novel antibiotic U-58,431 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces helicus Dietz and Li sp. n., NRRL 11461. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus, Streptococcus hemolyticus, and Streptococcus faecalis. It is also active against various Gram-negative bacteria, for example, Escherichia coli, Proteus vulgaris, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Salmonella schottmuelleri. It has strong activity against Diplococcus pneumoniae. Thus, antibiotic U-58,431 can be used in various environments to eradicate or control such bacteria.

Abstract: Antibiotic acanthomycin (U-53,827) produced by the controlled fermentation of the microorganism Streptomyces espinosus subsp. acanthus, NRRL 11081. This antibiotic and its base addition salts are active against Gram-positive bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.

Abstract: Antibiotic rubradirin C producible by the controlled fermentation of the known microorganism Streptomyces achromogenes var. rubradiris, NRRL 3061. This antibiotic and its base-addition salts are active against Streptococcus pyogenes and Bacillus cereus. Accordingly, they can be used in various environments to eradicate or control such microorganisms. SuBACKGROUND OF THE INVENTIONAntibiotic rubradirin, and a microbiological process for its preparation, are disclosed in U.S. Pat. No. 3,335,057. Rubradirin B is disclosed in U.S. application Ser. No. 787,833, filed Apr. 15, 1977. Degradation products of rubradirin and rubradirin B, and processes for their preparation are disclosed in U.S. application Ser. No. 793,785, filed May 5, 1977.BRIEF SUMMARY OF THE INVENTIONThe novel antibiotic of the invention, rubradirin C, is obtained by culturing Streptomyces achromogenes var. rubradiris, NRRL 3061, in an aqueous nutrient medium under aerobic conditions. The fermentation conditions disclosed in U.S. Pat. No.

Abstract: Antibiotic rubradirin B producible by the controlled fermentation of the known microorganism Streptomyces achromogenes var. rubradiris, NRRL 3061. This antibiotic and its base-addition salts are active against various microorganisms, for example, Staphylococcus aureus, Streptococcus hemolyticus, Sarcina lutea, and Mycobacterium avium. Accordingly, they can be used in various environments to eradicate or control such microorganisms.

Abstract: Antibiotic U-51,640 produced by the controlled fermentation of the microorganism Streptomyces ficellus Dietz, sp. n., NRRL 8067. This antibiotic and its acid addition salts are active against Gram-positive and Gram-negative bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.

Abstract: New antibiotic U-47,929 produced by the controlled fermentation of the new microorganism Streptomyces ficellus Dietz, sp. n., NRRL 8067. This antibiotic and its acid-addition salts are active against Gram-positive bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.

Abstract: New antibiotic U-48,266 produced by the controlled fermentation of the microorganism Streptomyces ficellus Dietz, sp. n., NRRL 8067. This antibiotic and its acid and base addition salts are active against Gram-positive and Gram-negative bacteria. Accordingly, they can be used in various environments to eradicate or control such bacteria.